ÇÑ¿ø½Ä ¸íÀÇ

¸Å³â 1000°Ç ÀÌ»ó À¯¹æ¾Ï ¼ö¼ú ÁøÇà

ÇÑ¿ø½Ä ¸íÀÇ

  • ¼Ò ¼Ó
    ¼­¿ï´ëº´¿ø ³»ºÐºñ¿Ü°ú
  • Àü¹®ºÐ¾ß
    À¯¹æ¾Ï

ÁÖ¿ä Áø·á ºÐ¾ß´Â À¯¹æ¾ÏÀ̸ç, ¸Å³â 1000·Ê ÀÌ»óÀÇ À¯¹æ¾Ï ¼ö¼úÀ» Çϰí ÀÖ´Ù.
ȯÀÚÀÇ ¾ÏÄ¡·á´Â ¹°·Ð »îÀÇ ÁúÀ» ³ôÀ̱â À§ÇØ ¼ö¼ú ÈÄ ¹Ì¿ëÀûÀÎ È¿°ú¸¦ ±Ø´ëÈ­ÇÏ´Â ¾Ï¼ºÇü¼ö¼ú ±â¹ýÀ» µµÀÔÇØ 2009³âºÎÅÍ ½ÃÇàÇϰí ÀÖ´Ù. ÀÌ ºÐ¾ßÀÇ ±¹³» ±ÇÀ§ÀÚ·Î ÅëÇÑ´Ù. Áö±Ý±îÁö 220Æí¿¡ ´ÞÇÏ´Â ±¹Á¦ ÇмúÁö ³í¹®À» ¹ßÇ¥Çß°í, À¯¹æ¾Ï À¯Àüü¸¦ ¿¬±¸ÇÏ¿© ÀÓ»óÀ¸·Î ¿¬°á½ÃŰ·Á´Â ³ë·ÂÀ» ÇØ¿À°í ÀÖ´Ù. 2012³â¿¡´Â ¼­¿ï´ëÀÇ´ë ¿ì¼ö¾÷Àû±³¼ö·Î »ÌÇû´Ù.

¸íÀÇÇÁ·ÎÇÊ ¸íÀÇ ÇÁ·ÎÇÊ

ÇзÂ

Educational Background
  • ¼­¿ï´ëÇб³ ÀϹݴëÇпø ¹Ú»ç°úÁ¤, ÀÇÇаú, ¿Ü°úÇÐ Àü°ø
  • ¼­¿ï´ëÇб³ ÀϹݴëÇпø ¼®»ç°úÁ¤, ÀÇÇаú ¿Ü°úÇÐ Àü°ø
  • ¼­¿ï´ëÇб³ Àǰú´ëÇÐ ÀÇÇаú
  • ¼­¿ï´ëÇб³ ÀÚ¿¬°úÇдëÇÐ ÀÇ¿¹°ú

ÁÖ¿ä°æ·Â

Work Experience
  • úÞ) ¼­¿ï´ëÇб³º´¿ø ¿Ü°ú ±³¼ö
  • úÞ) ¼­¿ï´ëÇб³º´¿ø ¾Ïº´¿ø À¯¹æ¼¾ÅÍÀå
  • úÞ) ¼­¿ï´ëÇб³ BK21 ÀÇ»ý¸í°úÇבּ¸»ç¾÷´Ü Âü¿©±³¼ö
  • úÞ) ¼­¿ï´ëÇб³º´¿ø ¿Ü°ú È«º¸´ã´ç±³¼ö
  • úÞ) ¼­¿ï´ëÇб³º´¿ø Peer Review Board À§¿ø

¼ö»ó³»¿ª

Awards List
  • 2012³â ¼­¿ï´ëÇб³ Àǰú´ëÇÐ ¿ì¼ö¾÷Àû±³¼ö

ÇÐȸȰµ¿

Academic activities
  • 2023.04 ~ ÇöÀçÇѱ¹À¯¹æ¾ÏÇÐȸ ÀÌ»çÀå
  • 2023.01 ~ ÇöÀçÇѱ¹À¯ÀüüÇÐȸ ºÎȸÀå
  • 2020.03 ~ ÇöÀç´ëÇѹα¹ÀÇÇÐÇѸ²¿ø ȸ¿ø
  • 2020.06 ~ ÇöÀçÇѱ¹º¸°ÇÀǷῬ±¸¿ø (NECA) ÀÇ·á±â¼úÀçÆò°¡ ÀÚ¹®À§¿ø
  • 2012 ~ ÇöÀçFull member of American Society of Clinical Oncology
  • 2012 ~ ÇöÀç´ëÇѾÏÇÐȸ ÀÌ»ç
  • 2011 ~ ÇöÀç´ëÇѾÏÇùȸ ÁýÇàÀÌ»ç
  • 2011 ~ ÇöÀç´ëÇѿܰúÇÐȸ ÆòÀÇ¿ø
  • 2009 ~ ÇöÀçEditorial board, International Journal of Breast Cancer (SAGE-Hindawi Access to Research)
  • 2007 ~ ÇöÀç´ëÇÑÀÓ»óÁ¾¾çÇÐȸ Æò»ýȸ¿ø èâ ´Ù¼ö
Àú¼­ ¾ÆÀÌÄÜ

ÁýÇÊÀú¼­

ÃÑ 3°Ç
Á¦ ¸ñ ÀÌÁ¨ µÎ·ÆÁö ¾Ê´Ù! À¯¹æ¾Ï
ÃâÆÇ»ç ÀÌÁ¨¹Ìµð¾î ¹ßÇàÀÏ 2009³â
Á¦ ¸ñ À¯¹æÇÐ
ÃâÆÇ»ç ÀÏÁ¶°¢ ¹ßÇàÀÏ 2005³â
Á¦ ¸ñ À¯¹æ¾Ï
ÃâÆÇ»ç ¾ÆÄ«µ¥¹Ì¾Æ ¹ßÇàÀÏ 2005³â
¿¬±¸ ¾ÆÀÌÄÜ

ÁÖ¿ä³í¹®

ÃÑ 7°Ç
Á¦ ¸ñ Circulation Time-Optimized Albumin Nanoplatform for Quantitative Visualization of Lung Metastasis via Targeting of Macrophages
¹ßÇ¥³âµµ 2022-8 ¹ßÇ¥Áö ACS NANO
Á¦ ¸ñ Targeting CLK4 inhibits the metastasis and progression of breast cancer by inactivating TGF-beta pathway (Jan, 10.1038/s41417-021-00419-0, 2022)
¹ßÇ¥³âµµ 2022-8 ¹ßÇ¥Áö CANCER GENE THERAPY
Á¦ ¸ñ Surgical margin status and survival outcomes of breast cancer patients treated with breast-conserving surgery and whole-breast irradiation after neoadjuvant chemotherapy
¹ßÇ¥³âµµ 2022-8 ¹ßÇ¥Áö BREAST CANCER RESEARCH AND TREATMENT
Á¦ ¸ñ Á¦¸ñ A nomogram for predicting three or more axillary lymph node involvement before breast cancer surgery
¹ßÇ¥³âµµ 2022-7 ¹ßÇ¥Áö SCIENTIFIC REPORTS
Á¦ ¸ñ Transcriptome analysis of SerpinB2-deficient breast tumors provides insight into deciphering SerpinB2-mediated roles in breast cancer progression
¹ßÇ¥³âµµ 2022-6 ¹ßÇ¥Áö BMC GENOMICS
Á¦ ¸ñ Reduced miR-371b-5p expression drives tumor progression via CSDE1/RAC1 regulation in triple-negative breast cancer
¹ßÇ¥³âµµ 2022-5 ¹ßÇ¥Áö ONCOGENE
Á¦ ¸ñ Spatial epitranscriptomics reveals A-to-I editome specific to cancer stem cell microniches
¹ßÇ¥³âµµ 2022-5 ¹ßÇ¥Áö NATURE COMMUNICATIONS

¸íÀÇqna ¸íÀÇ ¼Ò¼Óº´¿ø

¼­¿ï´ëº´¿ø

»ó±ÞÁ¾ÇÕº´¿ø
ÀüÈ­ ¾ÆÀÌÄÜ ´ëÇ¥¹øÈ£
1588-5700
À¥»çÀÌÆ® ¾ÆÀÌÄÜȨÆäÀÌÁö

ÁÖ¿ä½Ã¼³

ÀÀ±Þ½Ç ÀÀ±Þ½Ç
Ŭ¸®´Ð Ŭ¸®´Ð
Á¾ÇÕ°ËÁø¼¾ÅÍ Á¾ÇÕ°ËÁø¼¾ÅÍ
¾Ï¼¾ÅÍ ¾Ï¼¾ÅÍ
ÁÖÂ÷½Ã¼³ ÁÖÂ÷½Ã¼³

¼­¿ï´ëº´¿øÀº º»¿øÀ» ºñ·ÔÇÑ ¾î¸°À̺´¿ø, ¾Ïº´¿ø, ÀÇ»ý¸í¿¬±¸¿øÀ¸·Î ±¸¼ºµÅ ÀÖ´Â Á¾ÇÕ ÀÇ·á±â°üÀ¸·Î 1786º´»ó ±Ô¸ð¸¦ °®Ãß°í ÀÖ´Ù. 540¿© ¸íÀÇ ±³¼ö¿Í 5400¿© ¸íÀÇ Á÷¿øÀÌ ÇÏ·ç Æò±Õ 1700¿© ¸íÀÇ ÀÔ¿øÈ¯ÀÚ¿Í 8600¸íÀÌ ³Ñ´Â ¿Ü·¡È¯ÀÚ¸¦ µ¹º¸°í ÀÖ´Ù. ¼¼°èÀû ÷´Ü Áø·á ¿µ¿ªÀ» Áö¼ÓÀûÀ¸·Î È®º¸ÇÔÀ¸·Î½á ÃÖ»óÀÇ Áø·á ¼­ºñ½º¸¦ Á¦°øÇϰí, ¿ì¸®³ª¶ó ÀÇ·á ¼±ÁøÈ­¸¦ Ãß±¸ÇÏ´Â Á¤Ã¥ Çù·Â º´¿øÀÌ´Ù.

¼­¿ï´ëº´¿ø À̹ÌÁö

¼­¿ïƯº°½Ã Á¾·Î±¸ ´ëÇзΠ101

Ȩ
³»°¡ ¾Ë°íÀÖ´Â ¸íÀǸ¦ ÃßÃµÇØÁÖ¼¼¿ä